• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

31.44 -0.83 (-2.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Zenas BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
June 11, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine
June 02, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD
May 28, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress
May 19, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces First Subject Dosed in Phase 1 Clinical Trial of ZB021, a Novel, Potentially Best-in-Class Oral IL-17AA/AF Inhibitor
May 13, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 17, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
March 27, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock
March 26, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 16, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
February 09, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
February 03, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
January 27, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
January 20, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
January 13, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
January 06, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
January 05, 2026
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 19, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
December 15, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 12, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
November 11, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
October 27, 2025
From Zenas BioPharma
Via GlobeNewswire
News headline image
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
October 08, 2025
From Zenas BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap